Steward Partners Investment Advisory’s Zevra Therapeutics ZVRA Stock Holding History

Steward Partners Investment Advisory’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-600	Closed	-$4.16K	–	4115
2024 Q3	$4.16K	Hold	600	–	–	﹤0.01%	3248
2024 Q2	$2.94K	Hold	600	–	–	﹤0.01%	3197
2024 Q1	$3.48K	Hold	600	–	–	﹤0.01%	3149
2023 Q4	$3.93K	Hold	600	–	–	﹤0.01%	3052
2023 Q3	$2.89K	Hold	600	–	–	﹤0.01%	3003
2023 Q2	$3.06K	Hold	600	–	–	﹤0.01%	2942
2023 Q1	$3.3K	Hold	600	–	–	﹤0.01%	2914
2022 Q4	$2.75K	Hold	600	–	–	﹤0.01%	2946
2022 Q3	$4K	Hold	600	–	–	﹤0.01%	2888
2022 Q2	$3K	Sell	600 -150	-20%	-$684	﹤0.01%	2958
2022 Q1	$4K	Buy	+750	New	+$4.77K	﹤0.01%	2989
2021 Q2	–	Sell	-200	Closed	-$1.84K	–	7441
2021 Q1	$1.84K	Buy	+200	New	+$1.75K	﹤0.01%	3239

Other funds holding ZVRA

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steward Partners Investment Advisory's ZVRA Position: Q4 2024 in Review

Steward Partners Investment Advisory sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 600 shares — an estimated $4.16K sold.

Steward Partners Investment Advisory first reported a position in ZVRA in Q1 2021 and held it in 12 quarters. The position peaked at $4.16K in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

Steward Partners Investment Advisory reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
Steward Partners Investment Advisory sold 600 Zevra Therapeutics shares in Q4 2024, an estimated $4.16K.
Steward Partners Investment Advisory first reported a position in Zevra Therapeutics in Q1 2021 and held it in 12 quarters.
Steward Partners Investment Advisory's Zevra Therapeutics position peaked at $4.16K in Q3 2024.
109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Steward Partners Investment Advisory's 13F filing for Q4 2024, filed 6 Feb 2025.